TRANSVAGINAL DOPPLER PROBE, MODEL 09-0006-02

K023024 · Vascular Control Systems, Inc. · ITX · Sep 26, 2002 · Radiology

Device Facts

Record IDK023024
Device NameTRANSVAGINAL DOPPLER PROBE, MODEL 09-0006-02
ApplicantVascular Control Systems, Inc.
Product CodeITX · Radiology
Decision DateSep 26, 2002
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 892.1570
Device ClassClass 2
Attributes3rd-Party Reviewed

Intended Use

The Transvaginal Doppler Probe is intended for bilateral detection of uterine blood vessels.

Device Story

Transvaginal Doppler Probe is a ring-handled instrument with integrated 8 MHz pulsed-wave Doppler sensors; used for bilateral blood flow sensing of uterine blood vessels. Device connects to a portable transceiver box (Vascular Technology, Inc. Doppler Transceiver, 8 MHz Selectable Channel). Operates by emitting ultrasound waves to detect blood flow; output is processed by the transceiver for clinician review. Used in clinical settings by healthcare providers. Provides real-time blood flow detection to assist in clinical decision-making regarding uterine vascular status.

Clinical Evidence

Bench testing only. Compliance with IEC 60601-1 for electrical and thermal safety. Acoustic output power measurements performed per FDA guidance. No clinical data presented.

Technological Characteristics

Stainless steel construction; 8 MHz pulsed-wave Doppler sensor; ring-handled form factor; reusable; non-sterile; connects to external portable transceiver box; electrical/thermal safety per IEC 60601-1.

Indications for Use

Indicated for bilateral detection of uterine blood vessels in patients requiring uterine blood flow assessment.

Regulatory Classification

Identification

A diagnostic ultrasonic transducer is a device made of a piezoelectric material that converts electrical signals into acoustic signals and acoustic signals into electrical signals and intended for use in diagnostic ultrasonic medical devices. Accessories of this generic type of device may include transmission media for acoustically coupling the transducer to the body surface, such as acoustic gel, paste, or a flexible fluid container.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K023024 Vascular Control Systems, Inc. Transvaginal Doppler Probe SEP 2 6 2002 Confidential Premarket Notification (510(k)) #### SUMMARY OF SAFETY AND EFFECTIVENESS This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of the SMDA and 21 CFR 807.92. - 1. Submitter's name, address, telephone number, contact person, and date summary prepared: | a. | Submitter: | Vascular Control Systems, Inc.<br>32236-E Paseo Adelanto<br>San Juan Capistrano, CA 92675<br>(949) 488-8700 | |----|-----------------|-------------------------------------------------------------------------------------------------------------| | b. | Contact Person: | Al Memmolo<br>Vice President, Regulatory Affairs/Quality Assurance<br>(949) 488-8700 ext. 108 | - Date Summary Prepared: August 14, 2002 C. 2. Name of device, including trade name and classification name: | a. | Trade/Proprietary Name: | Transvaginal Doppler Probe | |----|-------------------------|--------------------------------------------------------| | b. | Classification name: | Diagnostic Ultrasonic Transducer<br>(21 CFR §892.1570) | - 3. Identification of the predicate device or legally marketed device or devices to which substantial equivalence is being claimed: | Company: | Koven Technology, Inc. | |---------------|----------------------------| | Device: | PW Doppler Vascular Probes | | 510(k): | K935994 | | Date Cleared: | May 11, 1995 | - 4. A description of the device that is the subject of the 510(k), including explanation of how the device functions, basic scientific concepts, significant physical and performance characteristics (design, material, physical properties): The Transvaginal Doppler Probe is a ring-handled instrument with integrated Doppler sensors, which allow for bilateral blood flow sensing of the uterine blood vessels by connecting to a commercially available portable transceiver box. The Transvaginal Doppler Probe is manufactured from stainless steel. {1}------------------------------------------------ #### ડ. Statement of intended use: The Transvaginal Doppler Probe is intended for bilateral detection of uterine blood vessels. #### 6. Statement of how the technological characteristics of the device compare to those of the predicate or legally marketed device. The Transvaginal Doppler Probe and the predicate device are both intended for detecting blood flow of blood vessels using an 8 MHz pulsed-wave Doppler sensor. The Doppler crystals in both devices are located at the distal end to allow for forward detection of blood flow. Both devices are constructed of stainless steel and are provided non-sterile, and are reusable. #### 7. Brief summary of nonclinical tests and results: The Transvaginal Doppler Probe has been designed and tested to comply with the requirements of IEC 60601-1 for electrical and thermal safety. Acoustic output power measurements were performed in accordance with the FDA Guidance document "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers". Test results indicate reliable performance when the device is used in accordance with the Instructions for Use. The Transvaginal Doppler Probe does not raise new issues of safety, effectiveness, or performance of the product. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the eagle. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 SEP 26 2002 Vascular Control Systems c/o Mr. Heinz Joerg Steneberg Division Manager Medical Division TÜV Rheinland of North America 12 Commerce Road NEWTOWN CT 06470 Re: K023024 Trade Name: Transvaginal Doppler Probe, Model 09-0006-02 Regulation Number: 21 CFR §892.1570 Regulation Name: Diagnostic ultrasound transducer Regulatory Class: Class II Product Code: 90 ITX Dated: August 19, 2002 Received: September 11, 2002 Dear Mr. Steneberg: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. This determination of substantial equivalence applies to the following transducers intended for use with the Transvaginal Doppler Probe, as described in your premarket notification: #### Transducer Model Number Model 09-0006-02 1.5x15mm 8MHz {3}------------------------------------------------ ## Page 2 - Mr. Heinz Joerg Steneberg - If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a post clearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Secking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded. The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to: > Food and Drug Administration Center for Devices and Radiological Health Document Mail Center (HFZ-401) 9200 Corporate Boulevard Rockville, Maryland 20850 This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801, please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your {4}------------------------------------------------ Page 3 – Mr. Heinz Joerg Steneberg responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597 or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html". If you have any questions regarding the content of this letter, please contact Mr. Rodrigo Perez at (301) 594-1212. Sincerely yours, David A. Bergman for llor Nancy C. Brogdon Director, Division of Reproductive, Abdominal and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ # l ransvaginal ### Diagnostic Ultrasound Indications for Use Form ## Fill out one form for each ultrasound system and each transducer. Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of he human body as follows: | | Mode of Operation | | | | | | | | | | |----------------------------------|-------------------|---|---|-----|-----|------------------|----------------------|------------------------------|-----------------------|--------------------| | Clinical Application | A | B | M | PWD | CWD | Color<br>Doppler | Amplitude<br>Doppler | Color<br>Velocity<br>Imaging | Combined<br>(specify) | Other<br>(specify) | | Ophthalmic | | | | | | | | | | | | Fetal | | | | | | | | | | | | Abdominal | | | | | | | | | | | | Intraoperative<br>(specify) | | | | | | | | | | | | Intraoperative<br>Neurological | | | | | | | | | | | | Pediatric | | | | | | | | | | | | Small Organ<br>(specify) | | | | | | | | | | | | Neonatal Cephalic | | | | | | | | | | | | Adult Cephalic | | | | | | | | | | | | Cardiac | | | | | | | | | | | | Transesophageal | | | | | | | | | | | | Transrectal | | | | | | | | | | | | Transvaginal | | | | N | | | | | | | | Transurethral | | | | | | | | | | | | Intravascular | | | | | | | | | | | | Peripheral Vascular | | | | | | | | | | | | Laparoscopic | | | | | | | | | | | | Musculo-skeletal<br>Conventional | | | | | | | | | | | | Musculo-skeletal<br>Superficial | | | | | | | | | | | | Other (specify) | | | | | | | | | | | N = new indication; P = previously cleared by FDA; E = added under Appendix E Additional Comments: Model 09-0006-02 The transducer is specified for use with the Vascular Technology, Inc. Doppler Transceiver, 8 MHz Selectable Channel, VTI P/N 108900 (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use (Per 21 CFR 801.109) ![]() (Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices 510(k) Number {6}------------------------------------------------ K023024 Indications for Use Statement 510(k) Number (if known): K013024 Page 1 of 1 Device Name: Transvaginal Doppler Probe Indications for Use: The Transvaginal Doppler Probe is intended for bilateral detection of uterine blood vessels. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices 510(k) Number_ Prescription Use OR Over-The-Counter-Use (Per 21 CFR 801.109)
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%